首页 > 最新文献

Critical reviews in clinical laboratory sciences最新文献

英文 中文
Development of circulating microRNA-based biomarkers for medical decision-making: a friendly reminder of what should NOT be done. 基于微rna的循环生物标志物在医疗决策中的发展:一个不应该做的友好提醒。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-03-01 DOI: 10.1080/10408363.2022.2128030
Päivi Lakkisto, Louise Torp Dalgaard, Thalia Belmonte, Sara-Joan Pinto-Sietsma, Yvan Devaux, David de Gonzalo-Calvo

Circulating cell-free microRNAs (miRNAs) represent a major reservoir for biomarker discovery. Unfortunately, their implementation in clinical practice is limited due to a profound lack of reproducibility. The great technical variability linked to major pre-analytical and analytical caveats makes the interpretation of circulating cell-free miRNA data challenging and leads to inconsistent findings. Additional efforts directed to standardization are fundamental. Several well-established protocols are currently used by independent groups worldwide. Nonetheless, there are some specific aspects in specimen collection and processing, sample handling, miRNA quantification, and data analysis that should be considered to ensure reproducibility of results. Here, we have addressed this challenge using an alternative approach. We have highlighted and discussed common pitfalls that negatively impact the robustness of circulating miRNA quantification and their application for clinical decision-making. Furthermore, we provide a checklist usable by investigators to facilitate and ensure the control of the whole miRNA quantification and analytical process. We expect that these recommendations improve the reproducibility of findings, and ultimately, facilitate the incorporation of circulating miRNA profiles into clinical practice as the next generation of disease biomarkers.

循环无细胞microRNAs (miRNAs)是发现生物标志物的主要储存库。不幸的是,由于严重缺乏可重复性,它们在临床实践中的实施受到限制。与主要的分析前和分析警告相关的巨大技术变异性使得对循环无细胞miRNA数据的解释具有挑战性,并导致不一致的发现。针对标准化的额外努力是至关重要的。目前,世界各地的独立团体正在使用几个完善的协议。尽管如此,在标本采集和处理、样品处理、miRNA定量和数据分析中,仍有一些具体的方面需要考虑,以确保结果的可重复性。在这里,我们使用另一种方法解决了这一挑战。我们强调并讨论了对循环miRNA量化的稳健性及其在临床决策中的应用产生负面影响的常见陷阱。此外,我们还提供了一份可供研究人员使用的清单,以促进和确保整个miRNA定量和分析过程的控制。我们期望这些建议能够提高研究结果的可重复性,并最终促进将循环miRNA谱作为下一代疾病生物标志物纳入临床实践。
{"title":"Development of circulating microRNA-based biomarkers for medical decision-making: a friendly reminder of what should NOT be done.","authors":"Päivi Lakkisto,&nbsp;Louise Torp Dalgaard,&nbsp;Thalia Belmonte,&nbsp;Sara-Joan Pinto-Sietsma,&nbsp;Yvan Devaux,&nbsp;David de Gonzalo-Calvo","doi":"10.1080/10408363.2022.2128030","DOIUrl":"https://doi.org/10.1080/10408363.2022.2128030","url":null,"abstract":"<p><p>Circulating cell-free microRNAs (miRNAs) represent a major reservoir for biomarker discovery. Unfortunately, their implementation in clinical practice is limited due to a profound lack of reproducibility. The great technical variability linked to major pre-analytical and analytical caveats makes the interpretation of circulating cell-free miRNA data challenging and leads to inconsistent findings. Additional efforts directed to standardization are fundamental. Several well-established protocols are currently used by independent groups worldwide. Nonetheless, there are some specific aspects in specimen collection and processing, sample handling, miRNA quantification, and data analysis that should be considered to ensure reproducibility of results. Here, we have addressed this challenge using an alternative approach. We have highlighted and discussed common pitfalls that negatively impact the robustness of circulating miRNA quantification and their application for clinical decision-making. Furthermore, we provide a checklist usable by investigators to facilitate and ensure the control of the whole miRNA quantification and analytical process. We expect that these recommendations improve the reproducibility of findings, and ultimately, facilitate the incorporation of circulating miRNA profiles into clinical practice as the next generation of disease biomarkers.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 2","pages":"141-152"},"PeriodicalIF":10.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9397688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. 白血病淋巴细胞增生性疾病流式细胞术分类的方法学和概念挑战。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-03-01 DOI: 10.1080/10408363.2022.2114418
Nadia Güell, Pablo Mozas, Alba Jimenez-Rueda, Milos Miljkovic, Jordi Juncà, Marc Sorigue

The diagnosis of leukemic B-cell lymphoproliferative disorders (B-LPDs) is made by integrating clinical, cytological, cytometric, cytogenetic, and molecular data. This leaves room for differences and inconsistencies between experts. In this study, we examine methodological and conceptual aspects of the flow cytometric classification of leukemic B-LPDs that could explain them. Among methodological aspects, we discuss (1) the different statistical tests used to select and evaluate markers, (2) how these markers are analyzed, (3) how scores are interpreted, (4) different degrees to which diagnostic information is used, and (5) and the impact of differences in study populations. Among conceptual aspects, we discuss (1) challenges to integrating different biological data points, (2) the under examination of the costs of misclassification (false positives and false negatives), and finally, (3) we delve into the impact of the lack of a true diagnostic gold standard and the indirect evidence suggesting poor reproducibility in the diagnosis of leukemic B-LPDs. We then outline current harmonization efforts and our personal approach. We conclude that numerous flow cytometry scores and diagnostic systems are now available; however, as long as the considerations discussed remain unaddressed, external reproducibility and interobserver agreement will not be achieved, and the field will not be able to move forward if a true gold standard is not found.

白血病b淋巴细胞增生性疾病(b - lpd)的诊断是通过综合临床、细胞学、细胞学、细胞遗传学和分子数据来完成的。这给专家之间的分歧和不一致留下了空间。在这项研究中,我们研究了白血病b - lpd的流式细胞术分类的方法学和概念方面,可以解释它们。在方法学方面,我们讨论(1)用于选择和评估标记的不同统计测试,(2)如何分析这些标记,(3)如何解释分数,(4)使用诊断信息的不同程度,以及(5)研究人群差异的影响。在概念方面,我们讨论了(1)整合不同生物学数据点的挑战,(2)对错误分类(假阳性和假阴性)成本的审查,最后,(3)我们深入研究了缺乏真正的诊断金标准和间接证据表明白血病b - lpd诊断可重复性差的影响。然后,我们概述当前的协调努力和我们个人的方法。我们的结论是,现在有许多流式细胞术评分和诊断系统;但是,只要所讨论的考虑因素没有得到解决,就无法实现外部可重复性和观察员间的协议,如果没有找到真正的黄金标准,该领域就无法向前发展。
{"title":"Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders.","authors":"Nadia Güell,&nbsp;Pablo Mozas,&nbsp;Alba Jimenez-Rueda,&nbsp;Milos Miljkovic,&nbsp;Jordi Juncà,&nbsp;Marc Sorigue","doi":"10.1080/10408363.2022.2114418","DOIUrl":"https://doi.org/10.1080/10408363.2022.2114418","url":null,"abstract":"<p><p>The diagnosis of leukemic B-cell lymphoproliferative disorders (B-LPDs) is made by integrating clinical, cytological, cytometric, cytogenetic, and molecular data. This leaves room for differences and inconsistencies between experts. In this study, we examine methodological and conceptual aspects of the flow cytometric classification of leukemic B-LPDs that could explain them. Among methodological aspects, we discuss (1) the different statistical tests used to select and evaluate markers, (2) how these markers are analyzed, (3) how scores are interpreted, (4) different degrees to which diagnostic information is used, and (5) and the impact of differences in study populations. Among conceptual aspects, we discuss (1) challenges to integrating different biological data points, (2) the under examination of the costs of misclassification (false positives and false negatives), and finally, (3) we delve into the impact of the lack of a true diagnostic gold standard and the indirect evidence suggesting poor reproducibility in the diagnosis of leukemic B-LPDs. We then outline current harmonization efforts and our personal approach. We conclude that numerous flow cytometry scores and diagnostic systems are now available; however, as long as the considerations discussed remain unaddressed, external reproducibility and interobserver agreement will not be achieved, and the field will not be able to move forward if a true gold standard is not found.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 2","pages":"83-100"},"PeriodicalIF":10.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9710703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lean and Six Sigma as continuous quality improvement frameworks in the clinical diagnostic laboratory. 精益和六西格玛作为临床诊断实验室的持续质量改进框架。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-01-01 DOI: 10.1080/10408363.2022.2106544
Vinita Thakur, Olatunji Anthony Akerele, Edward Randell

Processes to enhance customer-related services in healthcare organizations are complex and it can be difficult to achieve efficient patient-focused services. Laboratories make an integral part of the healthcare service industry where healthcare providers deal with critical patient results. Errors in these processes may cost a human life, create a negative impact on an organization's reputation, cause revenue loss, and open doors for expensive lawsuits. To overcome these complexities, healthcare organizations must implement an approach that helps healthcare service providers to reduce waste, variation, and work imbalance in the service processes. Lean and Six Sigma are used as continuous process improvement frameworks in laboratory medicine. Six Sigma uses an approach that involves problem-solving, continuous improvement and quantitative statistical process control. Six Sigma is a technique based on the DMAIC process (Define, Measure, Analyze, Improve, and Control) to improve quality performance. Application of DMAIC in a healthcare organization provides guidance on how to handle quality that is directed toward patient satisfaction in a healthcare service industry. The Lean process is a technique for process management in which waste reduction is the primary purpose; this is accomplished by implementing waste mitigation practices and methodologies for quality improvement. Overall, this article outlines the frameworks for continuous quality and process improvement in healthcare organizations, with a focus on the impacts of Lean and Six Sigma on the performance and quality service delivery system in clinical laboratories. It also examines the role of utilization management and challenges that impact the implementation of Lean and Six Sigma in clinical laboratories.

在医疗保健组织中,增强与客户相关的服务的流程非常复杂,很难实现高效的以患者为中心的服务。实验室是医疗保健服务行业不可或缺的一部分,医疗保健提供者在这里处理关键的患者结果。这些过程中的错误可能会造成人命损失,对组织的声誉造成负面影响,导致收入损失,并引发昂贵的诉讼。为了克服这些复杂性,医疗保健组织必须实现一种方法,帮助医疗保健服务提供者减少服务流程中的浪费、变化和工作不平衡。精益和六西格玛被用作检验医学的持续过程改进框架。六西格玛采用一种包括解决问题、持续改进和定量统计过程控制的方法。六西格玛是一种基于DMAIC过程(定义、测量、分析、改进和控制)来提高质量绩效的技术。DMAIC在医疗保健组织中的应用为医疗保健服务行业中如何处理旨在提高患者满意度的质量提供了指导。精益过程是一种以减少浪费为主要目的的过程管理技术;这是通过实施减少废物的做法和改进质量的方法来实现的。总之,本文概述了医疗保健组织中持续质量和流程改进的框架,重点是精益和六西格玛对临床实验室性能和质量服务交付系统的影响。它还检查了利用管理的作用和挑战,影响精益和六西格玛在临床实验室的实施。
{"title":"Lean and Six Sigma as continuous quality improvement frameworks in the clinical diagnostic laboratory.","authors":"Vinita Thakur,&nbsp;Olatunji Anthony Akerele,&nbsp;Edward Randell","doi":"10.1080/10408363.2022.2106544","DOIUrl":"https://doi.org/10.1080/10408363.2022.2106544","url":null,"abstract":"<p><p>Processes to enhance customer-related services in healthcare organizations are complex and it can be difficult to achieve efficient patient-focused services. Laboratories make an integral part of the healthcare service industry where healthcare providers deal with critical patient results. Errors in these processes may cost a human life, create a negative impact on an organization's reputation, cause revenue loss, and open doors for expensive lawsuits. To overcome these complexities, healthcare organizations must implement an approach that helps healthcare service providers to reduce waste, variation, and work imbalance in the service processes. Lean and Six Sigma are used as continuous process improvement frameworks in laboratory medicine. Six Sigma uses an approach that involves problem-solving, continuous improvement and quantitative statistical process control. Six Sigma is a technique based on the DMAIC process (Define, Measure, Analyze, Improve, and Control) to improve quality performance. Application of DMAIC in a healthcare organization provides guidance on how to handle quality that is directed toward patient satisfaction in a healthcare service industry. The Lean process is a technique for process management in which waste reduction is the primary purpose; this is accomplished by implementing waste mitigation practices and methodologies for quality improvement. Overall, this article outlines the frameworks for continuous quality and process improvement in healthcare organizations, with a focus on the impacts of Lean and Six Sigma on the performance and quality service delivery system in clinical laboratories. It also examines the role of utilization management and challenges that impact the implementation of Lean and Six Sigma in clinical laboratories.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 1","pages":"63-81"},"PeriodicalIF":10.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9396906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing. DropWise:干血点(DBS)、血液微采样及其在运动药物检测中的分析的当前作用和未来前景。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-01-01 DOI: 10.1080/10408363.2022.2103085
M Thevis, Katja Walpurgis, A Thomas

For decades, blood testing has been an integral part of routine doping controls. The breadth of information contained in blood samples has become considerably more accessible for anti-doping purposes over the last 10 years through technological advancements regarding analytical instrumentation as well as enhanced sample collection systems. Particularly, microsampling of whole blood and serum, for instance as dried blood spots (DBS), has opened new avenues in sports drug testing and substantially increased the availability and cost-effectiveness of doping control specimens. Thus, microvolume blood specimens possess the potential to improve monitoring of blood hormone and drug levels, support evaluation of circulating drug concentrations in competition, and enhance the stability of labile markers and target analytes in blood passport analyses as well as peptide hormone and steroid ester detection. Further, the availability of the fraction of lysed erythrocytes for anti-doping purposes warrants additional investigation, considering the sequestering capability of red blood cells (RBCs) for certain substances, as a complementary approach in support of the clean sport.

几十年来,血液检测一直是常规兴奋剂控制的一个组成部分。在过去的10年里,通过分析仪器的技术进步和增强的样本收集系统,血液样本中包含的信息广度已经变得更容易用于反兴奋剂目的。特别是,全血和血清的微采样,例如干血点(DBS),开辟了体育药物检测的新途径,并大大增加了兴奋剂控制标本的可用性和成本效益。因此,微体积血液标本具有改善血液激素和药物水平监测的潜力,支持竞争中循环药物浓度的评估,并增强血液护照分析以及肽激素和类固醇酯检测中不稳定标记物和目标分析物的稳定性。此外,考虑到红细胞(rbc)对某些物质的隔离能力,作为支持清洁运动的补充方法,用于反兴奋剂目的的溶解红细胞部分的可用性值得进一步调查。
{"title":"DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing.","authors":"M Thevis,&nbsp;Katja Walpurgis,&nbsp;A Thomas","doi":"10.1080/10408363.2022.2103085","DOIUrl":"https://doi.org/10.1080/10408363.2022.2103085","url":null,"abstract":"<p><p>For decades, blood testing has been an integral part of routine doping controls. The breadth of information contained in blood samples has become considerably more accessible for anti-doping purposes over the last 10 years through technological advancements regarding analytical instrumentation as well as enhanced sample collection systems. Particularly, microsampling of whole blood and serum, for instance as dried blood spots (DBS), has opened new avenues in sports drug testing and substantially increased the availability and cost-effectiveness of doping control specimens. Thus, microvolume blood specimens possess the potential to improve monitoring of blood hormone and drug levels, support evaluation of circulating drug concentrations in competition, and enhance the stability of labile markers and target analytes in blood passport analyses as well as peptide hormone and steroid ester detection. Further, the availability of the fraction of lysed erythrocytes for anti-doping purposes warrants additional investigation, considering the sequestering capability of red blood cells (RBCs) for certain substances, as a complementary approach in support of the clean sport.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 1","pages":"41-62"},"PeriodicalIF":10.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9334296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. 实验室生物标志物在囊性纤维化变应性支气管肺曲霉病诊断和治疗随访中的应用。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-01-01 DOI: 10.1080/10408363.2022.2101612
Sophie Steels, Marijke Proesmans, Xavier Bossuyt, Lieven Dupont, Glynis Frans

Allergic bronchopulmonary aspergillosis (ABPA), a severe inflammatory respiratory disease, is caused by a hypersensitivity reaction to the colonization of the airways with Aspergillus fumigatus. It is most often described in patients with asthma or cystic fibrosis. The diagnosis of ABPA is based on a combination of clinical, radiological, and immunological findings that have been included in different diagnostic criteria over the years. In this paper, we review the biomarkers included in these diagnostic criteria and novel research biomarkers that may be used in the diagnosis and treatment follow-up of ABPA in cystic fibrosis.

过敏性支气管肺曲霉病(ABPA)是一种严重的炎症性呼吸道疾病,是由对烟曲霉定植气道的超敏反应引起的。最常见于哮喘或囊性纤维化患者。ABPA的诊断是基于临床、放射学和免疫学结果的结合,这些结果已包括在多年来的不同诊断标准中。本文就这些诊断标准中包含的生物标志物以及可能用于囊性纤维化ABPA诊断和治疗随访的新研究生物标志物进行综述。
{"title":"Laboratory biomarkers in the diagnosis and follow-up of treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.","authors":"Sophie Steels,&nbsp;Marijke Proesmans,&nbsp;Xavier Bossuyt,&nbsp;Lieven Dupont,&nbsp;Glynis Frans","doi":"10.1080/10408363.2022.2101612","DOIUrl":"https://doi.org/10.1080/10408363.2022.2101612","url":null,"abstract":"<p><p>Allergic bronchopulmonary aspergillosis (ABPA), a severe inflammatory respiratory disease, is caused by a hypersensitivity reaction to the colonization of the airways with <i>Aspergillus fumigatus</i>. It is most often described in patients with asthma or cystic fibrosis. The diagnosis of ABPA is based on a combination of clinical, radiological, and immunological findings that have been included in different diagnostic criteria over the years. In this paper, we review the biomarkers included in these diagnostic criteria and novel research biomarkers that may be used in the diagnosis and treatment follow-up of ABPA in cystic fibrosis.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 1","pages":"1-24"},"PeriodicalIF":10.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9696076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. 钾likrein-激肽轴在sars -cov-2诱导的血管病理中的治疗相关性
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2023-01-01 DOI: 10.1080/10408363.2022.2102578
Dorsa Sohaei, Morley Hollenberg, Sok-Ja Janket, Eleftherios P Diamandis, Gennady Poda, Ioannis Prassas

While coronavirus disease 2019 (COVID-19) begins as a respiratory infection, it progresses as a systemic disease involving multiorgan microthromboses that underly the pathology. SARS-CoV-2 enters host cells via attachment to the angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 is widely expressed in a multitude of tissues, including the lung (alveolar cells), heart, intestine, kidney, testis, gallbladder, vasculature (endothelial cells), and immune cells. Interference in ACE2 signaling could drive the aforementioned systemic pathologies, such as endothelial dysfunction, microthromboses, and systemic inflammation, that are typically seen in patients with severe COVID-19. ACE2 is a component of the renin-angiotensin system (RAS) and is intimately associated with the plasma kallikrein-kinin system (KKS). As many papers are published on the role of ACE and ACE2 in COVID-19, we will review the role of bradykinin, and more broadly the KSS, in SARS-CoV-2-induced vascular dysfunction. Furthermore, we will discuss the possible therapeutic interventions that are approved and in development for the following targets: coagulation factor XII (FXII), tissue kallikrein (KLK1), plasma kallikrein (KLKB1), bradykinin (BK), plasminogen activator inhibitor (PAI-1), bradykinin B1 receptor (BKB1R), bradykinin B2 receptor (BKB2R), ACE, furin, and the NLRP3 inflammasome. Understanding these targets may prove of value in the treatment of COVID-19 as well as in other virus-induced coagulopathies in the future.

虽然2019冠状病毒病(COVID-19)最初是一种呼吸道感染,但它会发展为一种全身性疾病,涉及病理基础上的多器官微血栓形成。SARS-CoV-2通过附着血管紧张素转换酶2 (ACE2)受体进入宿主细胞。ACE2在多种组织中广泛表达,包括肺(肺泡细胞)、心脏、肠、肾、睾丸、胆囊、血管(内皮细胞)和免疫细胞。ACE2信号的干扰可能导致上述全身性病变,如内皮功能障碍、微血栓形成和全身性炎症,这些都是严重COVID-19患者的典型症状。ACE2是肾素-血管紧张素系统(RAS)的一个组成部分,与血浆钾化钙素-激肽系统(KKS)密切相关。由于许多关于ACE和ACE2在COVID-19中的作用的论文已经发表,我们将回顾缓激肽,更广泛地说,KSS在sars - cov -2诱导的血管功能障碍中的作用。此外,我们将讨论已批准和正在开发的针对以下靶点的可能的治疗干预措施:凝血因子XII (FXII)、组织激肽肽(KLK1)、血浆激肽肽(KLKB1)、纤溶酶原激活物抑制剂(PAI-1)、缓激肽B1受体(BKB1R)、缓激肽B2受体(BKB2R)、ACE、furin和NLRP3炎性体。了解这些靶点可能会在未来治疗COVID-19以及其他病毒诱导的凝血病中证明其价值。
{"title":"The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology.","authors":"Dorsa Sohaei,&nbsp;Morley Hollenberg,&nbsp;Sok-Ja Janket,&nbsp;Eleftherios P Diamandis,&nbsp;Gennady Poda,&nbsp;Ioannis Prassas","doi":"10.1080/10408363.2022.2102578","DOIUrl":"https://doi.org/10.1080/10408363.2022.2102578","url":null,"abstract":"<p><p>While coronavirus disease 2019 (COVID-19) begins as a respiratory infection, it progresses as a systemic disease involving multiorgan microthromboses that underly the pathology. SARS-CoV-2 enters host cells <i>via</i> attachment to the angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 is widely expressed in a multitude of tissues, including the lung (alveolar cells), heart, intestine, kidney, testis, gallbladder, vasculature (endothelial cells), and immune cells. Interference in ACE2 signaling could drive the aforementioned systemic pathologies, such as endothelial dysfunction, microthromboses, and systemic inflammation, that are typically seen in patients with severe COVID-19. ACE2 is a component of the renin-angiotensin system (RAS) and is intimately associated with the plasma kallikrein-kinin system (KKS). As many papers are published on the role of ACE and ACE2 in COVID-19, we will review the role of bradykinin, and more broadly the KSS, in SARS-CoV-2-induced vascular dysfunction. Furthermore, we will discuss the possible therapeutic interventions that are approved and in development for the following targets: coagulation factor XII (FXII), tissue kallikrein (KLK1), plasma kallikrein (KLKB1), bradykinin (BK), plasminogen activator inhibitor (PAI-1), bradykinin B1 receptor (BKB1R), bradykinin B2 receptor (BKB2R), ACE, furin, and the NLRP3 inflammasome. Understanding these targets may prove of value in the treatment of COVID-19 as well as in other virus-induced coagulopathies in the future.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"60 1","pages":"25-40"},"PeriodicalIF":10.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9341058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. 维生素D:来源,生理作用,生物动力学,缺乏,治疗用途,毒性,以及检测维生素D及其代谢物的分析方法概述。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-12-01 DOI: 10.1080/10408363.2022.2070595
Jiří Janoušek, Veronika Pilařová, Kateřina Macáková, Anderson Nomura, Jéssica Veiga-Matos, Diana Dias da Silva, Fernando Remião, Luciano Saso, Kateřina Malá-Ládová, Josef Malý, Lucie Nováková, Přemysl Mladěnka

Vitamin D has a well-known role in the calcium homeostasis associated with the maintenance of healthy bones. It increases the efficiency of the intestinal absorption of dietary calcium, reduces calcium losses in urine, and mobilizes calcium stored in the skeleton. However, vitamin D receptors are present ubiquitously in the human body and indeed, vitamin D has a plethora of non-calcemic functions. In contrast to most vitamins, sufficient vitamin D can be synthesized in human skin. However, its production can be markedly decreased due to factors such as clothing, sunscreens, intentional avoidance of the direct sunlight, or the high latitude of the residence. Indeed, more than one billion people worldwide are vitamin D deficient, and the deficiency is frequently undiagnosed. The chronic deficiency is not only associated with rickets/osteomalacia/osteoporosis but it is also linked to a higher risk of hypertension, type 1 diabetes, multiple sclerosis, or cancer. Supplementation of vitamin D may be hence beneficial, but the intake of vitamin D should be under the supervision of health professionals because overdosing leads to intoxication with severe health consequences. For monitoring vitamin D, several analytical methods are employed, and their advantages and disadvantages are discussed in detail in this review.

众所周知,维生素D在钙稳态中的作用与骨骼健康的维持有关。它能提高肠道对膳食钙的吸收效率,减少钙在尿液中的损失,并调动储存在骨骼中的钙。然而,维生素D受体在人体中无处不在,事实上,维生素D具有大量的非钙功能。与大多数维生素不同,充足的维生素D可以在人体皮肤中合成。然而,由于衣物、防晒霜、故意避免阳光直射或居住地的高纬度等因素,它的产生可能会显著减少。事实上,全世界有超过10亿人缺乏维生素D,而这种缺乏往往没有得到诊断。这种慢性缺乏不仅与佝偻病/骨软化症/骨质疏松症有关,而且还与高血压、1型糖尿病、多发性硬化症或癌症的高风险有关。因此,补充维生素D可能是有益的,但维生素D的摄入应在卫生专业人员的监督下进行,因为过量会导致中毒,对健康造成严重后果。本文综述了维生素D监测的几种分析方法,并详细讨论了它们的优缺点。
{"title":"Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites.","authors":"Jiří Janoušek,&nbsp;Veronika Pilařová,&nbsp;Kateřina Macáková,&nbsp;Anderson Nomura,&nbsp;Jéssica Veiga-Matos,&nbsp;Diana Dias da Silva,&nbsp;Fernando Remião,&nbsp;Luciano Saso,&nbsp;Kateřina Malá-Ládová,&nbsp;Josef Malý,&nbsp;Lucie Nováková,&nbsp;Přemysl Mladěnka","doi":"10.1080/10408363.2022.2070595","DOIUrl":"https://doi.org/10.1080/10408363.2022.2070595","url":null,"abstract":"<p><p>Vitamin D has a well-known role in the calcium homeostasis associated with the maintenance of healthy bones. It increases the efficiency of the intestinal absorption of dietary calcium, reduces calcium losses in urine, and mobilizes calcium stored in the skeleton. However, vitamin D receptors are present ubiquitously in the human body and indeed, vitamin D has a plethora of non-calcemic functions. In contrast to most vitamins, sufficient vitamin D can be synthesized in human skin. However, its production can be markedly decreased due to factors such as clothing, sunscreens, intentional avoidance of the direct sunlight, or the high latitude of the residence. Indeed, more than one billion people worldwide are vitamin D deficient, and the deficiency is frequently undiagnosed. The chronic deficiency is not only associated with rickets/osteomalacia/osteoporosis but it is also linked to a higher risk of hypertension, type 1 diabetes, multiple sclerosis, or cancer. Supplementation of vitamin D may be hence beneficial, but the intake of vitamin D should be under the supervision of health professionals because overdosing leads to intoxication with severe health consequences. For monitoring vitamin D, several analytical methods are employed, and their advantages and disadvantages are discussed in detail in this review.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"59 8","pages":"517-554"},"PeriodicalIF":10.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10615445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Technical quality assurance and quality control for medical laboratories: a review and proposal of a new concept to obtain integrated and validated QA/QC plans. 医学实验室的技术质量保证和质量控制:一个新概念的审查和建议,以获得完整和有效的QA/QC计划。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-12-01 DOI: 10.1080/10408363.2022.2088685
Huub H van Rossum

Technical quality assurance (QA) and quality control (QA/QC) are important activities within medical laboratories to ensure the adequate quality of obtained test results. QA/QC tools available at medical laboratories include external QC and internal QC, patient-based real-time quality control (PBRTQC) tools such as moving average quality control (MAQC), limit checks, delta checks, and multivariate checks, and finally, analyzer flagging. Recently, for PBRTQC tools, new optimization and validation methods based on error detection simulation have been developed to obtain laboratory-specific insights into PBRTQC error detection. These developments have enabled implementation and application of these individual tools in routine clinical practice. As a next step, they also enable performance comparison of the individual QA/QC tools and integration of all the individual QA/QC tools in order to obtain the most powerful and efficient QA/QC plans. In this review, a brief overview of the individual QA/QC tools and their characteristics is provided and the error detection simulation approaches are explained. Finally, a new concept entitled integrated quality assurance and control (IQAC) is presented. To enable IQAC, a conceptual framework is suggested and demonstrated for sodium, based on available published data. The proposed IQAC framework provides ways and tools by which the performance of different QA/QC tools can be compared in a so-called QA/QC error detection table to enable optimization and validation of the overall QA/QC plan in terms of alarm rate as well as pre-analytical, analytical, and post-analytical error detection performance.

技术质量保证(QA)和质量控制(QA/QC)是医学实验室确保获得的检测结果具有足够质量的重要活动。医学实验室可用的QA/QC工具包括外部QC和内部QC、基于患者的实时质量控制(PBRTQC)工具,如移动平均质量控制(MAQC)、极限检查、增量检查和多变量检查,最后是分析仪标记。最近,针对PBRTQC工具,开发了基于错误检测仿真的新的优化和验证方法,以获得实验室特定的PBRTQC错误检测。这些发展使这些单独的工具在常规临床实践中得以实施和应用。下一步,它们还可以对单个QA/QC工具进行性能比较,并集成所有单个QA/QC工具,以获得最强大和最有效的QA/QC计划。在这篇综述中,简要概述了各个QA/QC工具及其特性,并解释了错误检测模拟方法。最后,提出了综合质量保证与控制(IQAC)的概念。为了实现IQAC,根据现有的已发表数据,提出并演示了钠的概念框架。提出的IQAC框架提供了各种方法和工具,通过这些方法和工具,可以在所谓的QA/QC错误检测表中比较不同QA/QC工具的性能,从而在报警率以及分析前、分析中和分析后错误检测性能方面优化和验证整个QA/QC计划。
{"title":"Technical quality assurance and quality control for medical laboratories: a review and proposal of a new concept to obtain integrated and validated QA/QC plans.","authors":"Huub H van Rossum","doi":"10.1080/10408363.2022.2088685","DOIUrl":"https://doi.org/10.1080/10408363.2022.2088685","url":null,"abstract":"<p><p>Technical quality assurance (QA) and quality control (QA/QC) are important activities within medical laboratories to ensure the adequate quality of obtained test results. QA/QC tools available at medical laboratories include external QC and internal QC, patient-based real-time quality control (PBRTQC) tools such as moving average quality control (MAQC), limit checks, delta checks, and multivariate checks, and finally, analyzer flagging. Recently, for PBRTQC tools, new optimization and validation methods based on error detection simulation have been developed to obtain laboratory-specific insights into PBRTQC error detection. These developments have enabled implementation and application of these individual tools in routine clinical practice. As a next step, they also enable performance comparison of the individual QA/QC tools and integration of all the individual QA/QC tools in order to obtain the most powerful and efficient QA/QC plans. In this review, a brief overview of the individual QA/QC tools and their characteristics is provided and the error detection simulation approaches are explained. Finally, a new concept entitled integrated quality assurance and control (IQAC) is presented. To enable IQAC, a conceptual framework is suggested and demonstrated for sodium, based on available published data. The proposed IQAC framework provides ways and tools by which the performance of different QA/QC tools can be compared in a so-called QA/QC error detection table to enable optimization and validation of the overall QA/QC plan in terms of alarm rate as well as pre-analytical, analytical, and post-analytical error detection performance.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"59 8","pages":"586-600"},"PeriodicalIF":10.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10668719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Design, optimization, and application of multiplex rRT-PCR in the detection of respiratory viruses. 多重rRT-PCR检测呼吸道病毒的设计、优化及应用
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-12-01 DOI: 10.1080/10408363.2022.2072467
Jing Yang, Dandan Li, Jie Wang, Rui Zhang, Jinming Li

Viral respiratory infections are common and serious diseases. Because there is no effective treatment method or vaccine for respiratory tract infection, early diagnosis is vital to identify the pathogen so as to determine the infectivity of the patient and to quickly take measures to curb the spread of the virus, if warranted, to avoid serious public health problems. Real-time reverse transcriptase PCR (rRT-PCR), which has high sensitivity and specificity, is the best approach for early diagnosis. Among rRT-PCR methods, multiplex rRT-PCR can resolve issues arising from various types of viruses, high mutation frequency, coinfection, and low concentrations of virus. However, the design, optimization, and validation of multiplex rRT-PCR are more complicated than singleplex rRT-PCR, and comprehensive research on multiplex rRT-PCR methodology is lacking. This review summarizes recent progress in multiplex rRT-PCR methodology, outlines the principles of design, optimization and validation, and describes a scheme to help diagnostic companies to design and optimize their multiplex rRT-PCR detection panel and to assist laboratory staff to solve problems in their daily work. In addition, the analytical validity, clinical validity and clinical utility of multiplex rRT-PCR in viral respiratory tract infection diagnosis are assessed to provide theoretical guidance and useful information for physicians to understand the test results.

病毒性呼吸道感染是常见和严重的疾病。由于呼吸道感染没有有效的治疗方法或疫苗,早期诊断对于识别病原体以确定患者的传染性并在必要时迅速采取措施遏制病毒的传播至关重要,以避免严重的公共卫生问题。实时逆转录酶PCR (Real-time reverse transcripase PCR, rRT-PCR)具有较高的敏感性和特异性,是早期诊断的最佳方法。在rRT-PCR方法中,多重rRT-PCR可以解决病毒种类多、突变频率高、共感染、病毒浓度低等问题。然而,多重rRT-PCR的设计、优化和验证比单一rRT-PCR更为复杂,缺乏对多重rRT-PCR方法的全面研究。本文综述了多重rRT-PCR方法的最新进展,概述了设计、优化和验证的原则,并描述了一个方案,以帮助诊断公司设计和优化其多重rRT-PCR检测面板,并协助实验室工作人员解决日常工作中的问题。此外,评估多重rRT-PCR在病毒性呼吸道感染诊断中的分析效度、临床效度和临床应用价值,为医生了解检测结果提供理论指导和有用信息。
{"title":"Design, optimization, and application of multiplex rRT-PCR in the detection of respiratory viruses.","authors":"Jing Yang,&nbsp;Dandan Li,&nbsp;Jie Wang,&nbsp;Rui Zhang,&nbsp;Jinming Li","doi":"10.1080/10408363.2022.2072467","DOIUrl":"https://doi.org/10.1080/10408363.2022.2072467","url":null,"abstract":"<p><p>Viral respiratory infections are common and serious diseases. Because there is no effective treatment method or vaccine for respiratory tract infection, early diagnosis is vital to identify the pathogen so as to determine the infectivity of the patient and to quickly take measures to curb the spread of the virus, if warranted, to avoid serious public health problems. Real-time reverse transcriptase PCR (rRT-PCR), which has high sensitivity and specificity, is the best approach for early diagnosis. Among rRT-PCR methods, multiplex rRT-PCR can resolve issues arising from various types of viruses, high mutation frequency, coinfection, and low concentrations of virus. However, the design, optimization, and validation of multiplex rRT-PCR are more complicated than singleplex rRT-PCR, and comprehensive research on multiplex rRT-PCR methodology is lacking. This review summarizes recent progress in multiplex rRT-PCR methodology, outlines the principles of design, optimization and validation, and describes a scheme to help diagnostic companies to design and optimize their multiplex rRT-PCR detection panel and to assist laboratory staff to solve problems in their daily work. In addition, the analytical validity, clinical validity and clinical utility of multiplex rRT-PCR in viral respiratory tract infection diagnosis are assessed to provide theoretical guidance and useful information for physicians to understand the test results.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"59 8","pages":"555-572"},"PeriodicalIF":10.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The urocortin peptides: biological relevance and laboratory aspects of UCN3 and its receptor. 尿皮质素肽:UCN3及其受体的生物学相关性和实验室方面。
IF 1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2022-12-01 DOI: 10.1080/10408363.2022.2080175
Norah J Alghamdi, Christopher T Burns, Roland Valdes

The urocortins are polypeptides belonging to the corticotropin-releasing hormone family, known to modulate stress responses in mammals. Stress, whether induced physically or psychologically, is an underlying cause or consequence of numerous clinical syndromes. Identifying biological markers associated with the homeostatic regulation of stress could provide a clinical laboratory approach for the management of stress-related disorders. The neuropeptide, urocortin 3 (UCN3), and the corticotropin-releasing hormone receptor 2 (CRHR2) constitute a regulatory axis known to mediate stress homeostasis. Dysregulation of this peptide/receptor axis is believed to play a role in several clinical conditions including post-traumatic stress, sleep apnea, cardiovascular disease, and other health problems related to stress. Understanding the physiology and measurement of the UCN3/CRHR2 axis is important for establishing a viable clinical laboratory diagnostic. In this article, we focus on evidence supporting the role of UCN3 and its receptor in stress-related clinical syndromes. We also provide insight into the measurements of UCN3 in blood and urine. These potential biomarkers provide new opportunities for clinical research and applications of laboratory medicine diagnostics in stress management.

尿皮质素是属于促肾上腺皮质激素释放激素家族的多肽,已知可调节哺乳动物的应激反应。压力,无论是生理上的还是心理上的,都是许多临床综合征的潜在原因或后果。识别与压力稳态调节相关的生物标志物可以为管理压力相关疾病提供临床实验室方法。神经肽尿皮质素3 (UCN3)和促肾上腺皮质激素释放激素受体2 (CRHR2)构成已知的调节轴,介导应激稳态。这种肽/受体轴的失调被认为在几种临床状况中发挥作用,包括创伤后应激、睡眠呼吸暂停、心血管疾病和其他与压力相关的健康问题。了解UCN3/CRHR2轴的生理和测量对于建立可行的临床实验室诊断非常重要。在这篇文章中,我们关注支持UCN3及其受体在应激相关临床综合征中的作用的证据。我们还提供了对血液和尿液中UCN3的测量的见解。这些潜在的生物标志物为临床研究和实验室医学诊断在压力管理中的应用提供了新的机会。
{"title":"The urocortin peptides: biological relevance and laboratory aspects of UCN3 and its receptor.","authors":"Norah J Alghamdi,&nbsp;Christopher T Burns,&nbsp;Roland Valdes","doi":"10.1080/10408363.2022.2080175","DOIUrl":"https://doi.org/10.1080/10408363.2022.2080175","url":null,"abstract":"<p><p>The urocortins are polypeptides belonging to the corticotropin-releasing hormone family, known to modulate stress responses in mammals. Stress, whether induced physically or psychologically, is an underlying cause or consequence of numerous clinical syndromes. Identifying biological markers associated with the homeostatic regulation of stress could provide a clinical laboratory approach for the management of stress-related disorders. The neuropeptide, urocortin 3 (UCN3), and the corticotropin-releasing hormone receptor 2 (CRHR2) constitute a regulatory axis known to mediate stress homeostasis. Dysregulation of this peptide/receptor axis is believed to play a role in several clinical conditions including post-traumatic stress, sleep apnea, cardiovascular disease, and other health problems related to stress. Understanding the physiology and measurement of the UCN3/CRHR2 axis is important for establishing a viable clinical laboratory diagnostic. In this article, we focus on evidence supporting the role of UCN3 and its receptor in stress-related clinical syndromes. We also provide insight into the measurements of UCN3 in blood and urine. These potential biomarkers provide new opportunities for clinical research and applications of laboratory medicine diagnostics in stress management.</p>","PeriodicalId":10760,"journal":{"name":"Critical reviews in clinical laboratory sciences","volume":"59 8","pages":"573-585"},"PeriodicalIF":10.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9184699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Critical reviews in clinical laboratory sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1